Comparing Jardiance and Farxiga: Which Diabetes Medication Might Suit You Better?
In the world of diabetes management, two medications stand out for their effectiveness in controlling blood sugar levels: Jardiance (empagliflozin) and Farxiga (dapagliflozin). While both drugs are commonly used to treat type 2 diabetes, they have distinct differences in effectiveness, side effects, and cost.
Effectiveness
When it comes to reducing HbA1c levels and improving cardiovascular outcomes, Jardiance has a slight edge, particularly in reducing cardiovascular death, especially in heart failure cases. It has also been proven to lower the risk of heart-failure hospitalization and mortality in adults, with or without diabetes.
Farxiga, on the other hand, boasts broader evidence supporting kidney (renal) benefits compared to Jardiance. It has demonstrated effectiveness for heart failure and renal outcomes, although its cardiovascular death reduction is slightly less compared to Jardiance.
Side Effects
Both Jardiance and Farxiga share common side effects related to urinary tract infections and yeast infections. However, serious side effects are rare but clinically important to monitor. Notable rare side effects for Jardiance include diabetic ketoacidosis, dehydration, hypoglycemia, and possible allergic reactions. For Farxiga, there are no major differences reported in its side effect profile compared to Jardiance.
Cost
Jardiance, being a brand-name medication, currently has no generic available, making it relatively expensive. On the other hand, Farxiga may offer more cost flexibility through generics or discounts, depending on market availability.
Patients should discuss with their healthcare providers to choose the medication that best fits their medical condition, risk factors, and financial situation.
It is essential to note that both Jardiance and Farxiga are not approved for treating type 1 diabetes.
For severe allergic reaction symptoms, such as swelling or trouble breathing, call 911 or your local emergency number right away.
Both medications can cause serious side effects, including dehydration, low blood pressure, ketoacidosis, kidney damage, serious UTIs, Fournier's gangrene, low blood sugar when used together with insulin, and allergic reactions.
In conclusion, while Jardiance might be more effective in reducing cardiovascular death and improving heart failure outcomes, Farxiga has broader evidence supporting kidney benefits. Both drugs share similar common side effects, and their cost varies due to market availability and the presence of generic versions. It is crucial to consult with a healthcare provider to make an informed decision about the best medication for individual needs.
- Jardiance has a slightly better record in reducing HbA1c levels and improving cardiovascular outcomes compared to Farxiga, especially in cases of heart failure.
- Farxiga offers broader evidence supporting renal benefits compared to Jardiance, despite a slightly less reduction in cardiovascular death.
- Common side effects shared by both Jardiance and Farxiga include urinary tract infections and yeast infections, but rare side effects are worth monitoring.
- Jardiance, as a brand-name medication, is relatively expensive due to the lack of generics, while Farxiga might offer more cost flexibility.
- Seekers should discuss with their healthcare providers to choose the most suitable medication based on their medical condition, risk factors, and financial situation.
- Both Jardiance and Farxiga are not approved for treating type 1 diabetes.
- In the event of a severe allergic reaction, seek immediate medical help by calling 911 or your local emergency number right away.
- Both medications can cause serious side effects, including dehydration, low blood pressure, ketoacidosis, kidney damage, serious UTIs, Fournier's gangrene, low blood sugar when used together with insulin, and allergic reactions.
- The field of science and medical-conditions continues to research and develop predictive models for better understanding and managing chronic diseases, such as diabetes, heart diseases, and chronic kidney disease (CKD).
- Type-2 diabetes treatment seekers might benefit from new drug developments and health-and-wellness initiatives aimed at reducing obesity, a leading contributor to type-2 diabetes.
- Switchers, interested in exploring alternative treatments or combating drug resistance, should stay updated on the latest advancements in medical research and science to make informed decisions regarding their treatment options.
